Prytime Medical Closes Funding Round to Support Commercialization of Reboa Products

June 2, 2021—Prytime Medical Devices, Inc. announced the closing of a $6 million inside financing round to support commercialization of their Reboa products for resuscitative endovascular balloon occlusion of the aorta for truncal hemorrhage control.

The funding round will also support a key shift in the company’s commercial focus away from simply product familiarization toward customer support and quality clinical outcomes.

On May 24, the company announced it received both United Kingdom and CE Mark approval for its next-generation ER-Reboa Plus catheter. The device previously received approvals in the United States and Canada.

David Spencer, CEO of Prytime, commented in the company’s press release, “Our growth is based on experience from over 4 years of market engagement and 7,500 clinical uses worldwide. We see two key characteristics of successful Reboa programs. The first is the practice of ‘Team Reboa’, and the second is the implementation of a rigorous ‘Early Access protocol’. This funding will enable us to support our customers not just with our extensive Reboa-knowledge base, but also by sharing the experience of other Reboa users. This new focus will support strong clinical outcomes more effectively and enable enhanced peer-to-peer knowledge sharing. It is strongly resonating with the user community.”